Article Text

This article has a correction. Please see:

PDF
Trends in the prevalence and incidence of diabetes in the UK: 1996–2005
  1. E L Massó González1,
  2. S Johansson2,3,
  3. M-A Wallander2,4,
  4. L A García Rodríguez1
  1. 1
    Spanish Centre for Pharmacoepidemiological Research (CEIFE), Madrid, Spain
  2. 2
    AstraZeneca R&D, Mölndal, Sweden
  3. 3
    Institute of Medicine, Sahlgrenska Academy Göteborg University, Sweden
  4. 4
    Department of Public Health and Caring Science, Uppsala University, Sweden
  1. Ms E L Massó González, Spanish Centre for Pharmacoepidemiological Research (CEIFE), Almirante 28, 2°, 28004 Madrid, Spain; elviraceife{at}telefonica.net

Abstract

Background: To estimate the incidence and prevalence of type 1 and type 2 diabetes in the UK general population from 1996 to 2005.

Methods: Using The Health Improvement Network database, patients with type 1 or type 2 diabetes were identified who were 10–79 years old between 1996 and 2005. Prevalent cases (n = 49 999) were separated from incident cases (n = 42 642; type 1 = 1256, type 2 = 41 386). Data were collected on treatment patterns in incident cases, and on body mass index in prevalent and incident cases.

Results: Diabetes prevalence increased from 2.8% in 1996 to 4.3% in 2005. The incidence of diabetes in the UK increased from 2.71 (2.58–2.85)/1000 person-years in 1996 to 4.42 (4.32–4.53)/1000 person-years in 2005. The incidence of type 1 diabetes remained relatively constant throughout the study period; however, the incidence of type 2 diabetes increased from 2.60 (2.47–2.74)/1000 person-years in 1996 to 4.31 (4.21–4.42)/1000 person-years in 2005. Between 1996 and 2005, the proportion of individuals newly diagnosed with type 2 diabetes who were obese increased from 46% to 56%. Treatment with metformin increased across the study period, while treatment with sulphonylureas decreased.

Conclusions: The prevalence and incidence of type 2 diabetes have increased in the UK over the past decade. This might be primarily explained by the changes in obesity prevalence. Also, there was a change in drug treatment pattern from sulphonylureas to metformin.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Competing interests: None.

  • Funding: This study was funded by a unrestricted research grant from AstraZeneca R&D Mölndal, Sweden.

  • Ethics approval: Ethics approval was received from the Multi-centre Research Ethics Committee (MREC)UK-MREC-South-East.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • PostScript
    BMJ Publishing Group Ltd